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1. Introduction 
Chronic kidney disease (CKD) or reduced renal function with advanced age is highly 
prevalent in the elderly (Hill et al., 2016). There is growing evidence that impaired renal 
function is associated with cardiovascular diseases (Ix, Shlipak, Chertow and Whooley, 2007; 
Matsushita et al., 2012), all-cause mortality (Shlipak et al., 2005) and cognitive decline 
(Buchman et al., 2009) in the elderly. Generally, the glomerular filtration rate (GFR) 
estimated from the serum creatinine is considered the best overall index of renal 
function in the clinical practice (Traynor, Mactier, Geddes and Fox, 2006). However, serum 
creatinine levels are influenced by age, gender, body weight and muscle mass (Stevens, 
Coresh, Greene and Levey, 2006). Consequently, cystatin C has been identified as a novel 
alternative endogenous marker of renal function and is more sensitive than creatinine 
(Rule, Bailey, Lieske, Peyser and Turner, 2013; Shardlow et al., 2017). Previous studies suggest 
that the cystatin C level has a stronger association with cardiovascular disease and 
mortality than do serum creatinine and GFR in the elderly (Shlipak et al., 2005). Blood 
urea nitrogen (BUN) is a serum byproduct of protein metabolism and is used to evaluate 
renal function (Macedo, 2011). The BUN concentration rises as renal function decreases; 
however, BUN may vary independently of the GFR (Lopez-Giacoman and Madero, 2015). 
 
Depressive symptoms are a major global public health problem. Depression is also 
highly common among the elderly and is linked to a wide range of adverse health 
outcomes including cardiovascular disease and mortality (Ye et al., 2013). It is estimated 
that approximately 26.5% of individuals with CKD experience depressive symptoms, 
and this number rises to 40% for the subset of individuals who require dialysis treatment 
(Palmer et al., 2013). Participants with kidney impairment suffer severe psychological 
distress (Tong et al., 2009), and they have a 3-fold higher risk of depressive symptoms 
than individuals without kidney impairment (Palmer et al., 2013). Additionally, 
depressive symptoms increase the risk of end-stage renal disease by 66% (Tsai et al., 
2012). The majority of previous studies have focused on the impact of depressive 
symptoms on the risk of CKD or death (Ix, Shlipak, Chertow and Whooley, 2007; Shlipak et 
al., 2005; Tsai et al., 2012; Wu et al., 2010); however, research on the relationship between 
renal function and depressive symptoms in the general population are scarce and 
conflicting. For example, Odden et al. conducted a cross-sectional study of 967 patients 
with cardiovascular disease who were enrolled in the Heart and Soul Study; this study 
showed that impaired renal function, as indicated by creatinine clearance, was not 
associated with depressive symptoms (Odden, Whooley and Shlipak, 2006). In the 
Maastricht Study, high albuminuria levels were cross-sectionally associated with 
depressive symptoms (Martens et al., 2016). In addition, in the Health, Aging and Body 
Composition Study of 3075 subjects aged 70-79 years over 6 years of follow up, Minev 
et al. found that a high cystatin C (>1.25 mg/l) was associated with a 2-fold increased 
risk of depressive symptoms (Minev et al., 2010). However, this association has not been 
adequately evaluated among older adults with normal renal function. 
 
To the best of our knowledge, no study has compared the effects of various renal 
function measurements on the risk of depressive symptoms in a middle-aged adult with 
normal renal function. Therefore, we aimed to examine the associations of cystatin C, 
BUN and the estimated GFR with the risk of depressive symptoms in a population-
based cohort study of middle-aged Chinese adults. We hypothesized that cystatin C 
would be a stronger and linear predictor of the risk of depressive symptoms among 
subjects with normal function than the BUN or GFR. 
 
2. Methods 
2.1. Study Participants 
The China Health and Retirement Longitudinal Study (CHARLS) is a community-
based, national representative longitudinal study that was initiated in 2011-2012 (Zhao, 
Hu, Smith, Strauss, and Yang, 2014). The main objective of CHARLS is to evaluate the 
main health and economic issues associated with rapid population aging in China. 
Briefly, 17708 individuals aged 45 years or older were randomly recruited from 150 
counties or districts from 28 provinces using a four-stage, stratified, and cluster 
sampling method. Among those participants, 11847 individuals provided fasting blood 
samples. A description of the study design, quality control procedures, laboratory 
methods, and procedures for physical examination can be found on the CHARLS 
website (http://charls.pku.edu.cn/en). The ethical committees of Peking University 
approved the study protocol, and all participants provided written informed consent. 
For this analysis, 5111 participants without depressive symptoms, whose serum was 
available for the measurement of cystatin C, and who had a normal renal function (GFR 
≥60 ml/min/1.73 m2) were included. The cohort selection of flowchart is included in 
the Supplementary Materials (Figure S1).  
 
2.2. Measurements of Renal Function 
Serum from fasting blood samples was stored at -70°C until analysis at the Center for 
Clinical Laboratory of Capital Medical University. Cystatin C was measured using a 
particle-enhanced turbidimetric assay (Voskoboev, Larson, Rule and Lieske, 2012). The 
intra-individual coefficient of variation (CV) was <5%, and the between-individual CV 
was <5%. The detection range of the assay was 0.5 to 8.0 mg per liter. The serum 
creatinine level was measured using a rate-blanked and compensated Jaffe creatinine 
method. The intra-individual CV was <1.6%, and the between-individual CV was 
<2.1%. The detection range of the assay was 0.1 to 25 mg/dL. We estimated the GFR 
using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine 
equation (Levey et al., 2009). The BUN was measured using an enzymatic UV method 
with urease. The intra-individual CV was <4.4%, and the between-individual CV was 
<4.1%. The range of detection of the assay was 5 to 100 mg/dL. 
 
2.3. Ascertainment of Depressive Symptoms  
Depressive symptoms were evaluated at baseline and every two years at follow-up 
using the 10-item Center for Epidemiologic Studies Depressive Symptoms Scale (CES-
D) short form (Andresen, Malmgren, Carter and Patrick, 1994). To clarify frequency of the 
mood and behavioral symptoms, participants were asked to rate how often they 
experienced then symptoms during the previous week: (1) I was bothered by things that 
do not usually bother me; (2) I had trouble keeping my mind on what I was doing; (3) 
I felt depressed; (4) I felt everything I did was an effort; (5) I felt hopeful about the 
future; (6) I felt fearful; (7) My sleep was restless; (8) I was happy; (9) I felt lonely; (10) 
I could not get “going”. Each item was scored on a 4-point Likert scale ranging from 0 
(“not at all”) to 3 (“nearly every day”). Items 5 and 8 were reversely scored before 
analysis. In the current analysis, individuals missing three or more responses on the 
CES-D were excluded. Therefore, the total CES-D scores ranged from 0 to 30, with a 
higher score representing a greater level of depressive symptoms. The 10-item CES-D 
has been widely validated among older Chinese adults and shows satisfactory 
psychometric properties (Boey, 1999; Chen and Mui, 2014; Cheng and Chan, 2005). A recent 
validation study conducted in a subsample of 742 CHARLS participants aged ≥60 years 
showed that the two-factor model was the best fit, and the completely standardized 
factor loadings were ≥0.30 (Chen and Mui, 2014). Following the validation study, the 
binary depressive symptoms were defined as total CES-D scores of 12 or higher in the 
current study (Chen and Mui, 2014). We excluded those individuals who had depressive 
symptoms at baseline.  
 
2.3. Assessment of Covariates  
Baseline demographic and risk factors were collected by trained personnel according 
to standard procedures. Sociodemographic factors, including age, sex, residential area 
(urban, rural), education level (no formal education, primary school, middle school or 
above), marital status (unmarried, married) and retirement status (retired, nonretired) 
were self-reported. Health behaviors including smoking (never, former, current), 
alcohol use (never, <1 times/month, ≥1 times/month) were assessed using a 
questionnaire. Self-reported health was recoded into three categories (very good/good, 
fair, poor/very poor). Life satisfaction was recoded into three categories 
(completely/very satisfied, somewhat satisfied, not very/not at all satisfied). Family-
based social support was assessed by evaluating the family-based network size 
measured by the number of core family members, whether the respondent had received 
help and whether the respondent had provided help (Shen and Yeatts, 2013). Social 
participation was assessed by respondent participation in the following social activities: 
(1) interacted with a friend; (2) played mahjong, or went to a sport, social or other kind 
of club; (3) took part in a community-related organization; (4) took part in a 
community-related organization; (5) took part in voluntary or charity work; (6) attended 
an educational or training course (Tu et al., 2018). The body mass index (BMI) was 
calculated as the weight in kilograms divided by the height in meters squared. Sitting 
blood pressure was measured three times after a 5-min rest period in quiet space using 
an OmronTM HEM-7200 Monitor, and an average of three values was obtained for the 
systolic blood pressure (SBP) and diastolic blood pressure (DBP). The self-reported 
prior history of physician-diagnosed diseases included hypertension, diabetes mellitus, 
dyslipidemia, coronary artery heart disease, stroke, and obstructive pulmonary disease. 
Using plasma samples, the total cholesterol (TC), low-density lipoprotein cholesterol 
(LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), fasting 
blood glucose (FBG), and C-reactive protein (CRP) levels were measured using 
standard assays (Yang et al., 2016).  
 
2.4. Statistical Analysis 
All statistical analyses were performed using Stata/MP, version 14.1, and 2-sided P 
values <0.05 were considered statistically significant. In the cohorts, the data were 80% 
complete in relation to potential confounders. We first used multiple imputation with 
multivariable chained equations to impute missing data for continuous variables (BMI, 
SBP, DBP, HDL-C, LDL-C, and FBG) and categorical variables (retirement status, 
receiving help, providing help, self-reported health and life satisfaction) (Harel and Zhou, 
2007). Because family-network size, TG and CRP values were not normally distributed, 
log transformation was used. Participants were divided into five groups based on the 
quintiles of cystatin C levels based on values for the entire cohort (<0.82 mg/l, 0.83-
0.93 mg/l, 0.94-1.02 mg/l, 1.03-1.16 mg/l, and ≥1.17 mg/l). The P value for linear trend 
across the quintiles was calculated from the logistic regression for categorical variables 
and linear regression for continuous variables.  
 
To evaluate the association of each renal function measurement with depressive 
symptoms, we initially created quintiles of the study population according to the 
cystatin C, BUN and estimated GFR levels. We used a modified Poisson regression 
with robust error variance (McNutt, Wu, Xue and Hafner, 2003) to evaluate the likelihood 
of developing depressive symptoms (yes or no) at follow-up for each index of renal 
function among participants who were free of depressive symptoms at baseline. 
Incidence risk ratio (IRR) and the corresponding 95% confidence interval (CI) were 
reported. The main analysis was based on the combined the results obtained by running 
each model in 10 independent imputed data sets. Potential confounding variables for 
statistical adjustment were chosen a priori according to known associations with 
depressive symptoms and renal function. The analysis was adjusted for age, sex, 
education, marital status, living area, alcohol use, smoking status, retirement status, 
social participation, family-based social support, self-reported health, life satisfaction, 
history of hypertension, diabetes, dyslipidemia, coronary artery heart disease, stroke, 
and chronic obstructive pulmonary disorder, SBP, BMI, TC, LDL-C, HDL-C, baseline 
CES-D score and log-transformed TG, and log-transformed CRP level. For tests of 
linear trend, we applied linear terms using the median of each renal function 
measurement quintile. The association of cystatin C, BUN or the estimated GFR with 
depressive symptoms were also assessed as a continuous scale (per 1-SD change). 
 
Furthermore, the association between incident depressive symptoms and cystatin C 
levels on a continuous scale was examined using restricted cubic splines with 3 knots 
located at the 10th, 50th, and 90th percentiles (Harrell, 2010) of cystatin C incorporated 
in a modified Poisson regression. A cystatin C concentration of 1 mg/l was used as the 
reference value for this analysis because it approximated the median value. Sensitivity 
analysis using complete data (n=4128) was conducted to examine the association 
between measurements of renal function and depressive symptoms. 
 
3. Results 
3.1. Study Participants  
Among the 5111 individuals included in this analysis, the overall mean (±SD) serum 
cystatin C was 0.99 ± 0.21 mg/l (1st to 99th percentile range, 0.55 to 1.58 mg/l). The 
baseline characteristics of the participants are shown in Table 1. The participants with 
the highest cystatin C levels were more likely to be older, male, and current smokers 
and drinkers, compared with participants with lower cystatin C levels (Table 1). Nearly 
all of the coexisting conditions were more prevalent among those with elevated levels 
of cystatin C (Table 1). 
 
3.2. Incidence Rate of Depressive symptoms  
During 4 years of follow-up, 1746 (34.16%) individuals developed new-onset 
depressive symptoms. The crude incidence rate of depressive symptoms across each 
quintile of cystatin C, BUN, and estimated GFR are shown in Figure 1.  
 
3.3. Renal Function with Depressive symptoms 
Table 2 shows the IRR and 95% CI of depressive symptoms according to measures of 
renal function. After multivariate adjustment, compared to those with the lowest level 
of cystatin C (Quintile 1), individuals with the highest level of cystatin C (Quintile 5) 
had an adjusted IRR of 1.18 (95% CI: 1.03-1.35) for depressive symptoms. Individuals 
with an intermediate BUN level (Quintile 3) were at lower risk of depressive symptoms 
(IRR: 0.86, 95% CI: 0.76-0.97). Individuals with lower estimated GFR values were 
showed an at increased depressive symptoms risk (IRR: 1.15, 95% CI: 1.01-1.31). The 
association remained robust when analysis limited to complete data (Table S1). 
 
3.4 Dose-Response Analysis  
The restricted cubic spline analysis suggested a linear relationship between cystatin C 
and depressive symptoms (Figure 2). The multivariate-adjusted IRR using serum 
cystatin C levels on a continuous scale was 1.13 (95% CI: 1.08-1.19) per 1-SD change 
(Figure 3). The association between the BUN and estimated GFR on a continuous scale 
and depressive symptoms were not statistically significantly (Figure 3). 
 
4. Discussion  
Our results demonstrate that the cystatin C concentration is linearly and independently 
associated with new-onset depressive symptoms in a general population with a 
creatinine-based estimated GFR of 60 mL/min/1.73 m2 or greater. In contrast, the BUN 
level and estimated GFR on a continuous scale had no statistically significant 
association with depressive symptoms in the fully adjusted model. 
  
4.1. Association between Renal Function and Depressive Symptoms 
Depressive symptoms are a major contributor to the global disease burden and are 
highly prevalent in patients with chronic kidney disease or end-stage renal disease. A 
recent meta-analysis reported that the prevalence of depressive symptoms was as high 
as 40% among CKD patients (Palmer et al., 2013). Several previous studies suggested 
that impaired renal function measured by estimated GFR may be associated with 
depressive symptoms (Abdel-Kader, Unruh and Weisbord, 2009; Fischer et al., 2012; Liu et al., 
2018), whereas other studies did not find this association (Campbell et al., 2013; Fischer et 
al., 2010; Martens et al., 2016). For example, in the Chronic Renal Insufficiency Cohort 
(CRIC) Study, Fischer et al. found that there were an 8% increased odds of depressive 
symptoms for every 10 ml/min/1.73 m2 decrease in GFR in the fully adjusted model 
(Fischer et al., 2012). This association was also observed in an older Chinese cross-
sectional study (Liu et al., 2018). Furthermore, a recent meta-analysis conducted by Lee 
et al. demonstrated that self-management programs for the estimated GFR improved 
depressive symptoms in CKD patients (Lee, Wu, Hsieh and Tsai, 2016). Additionally, in 
the Diabetes Study of Northern California survey, older adults in the lowest estimated 
GFR category (≤29 mL/min/1.73 m2) were cross-sectionally demonstrated to have 
twice the probability of depressive symptoms compared with these with the normal 
estimated GFR category ≥90 mL/min/1.73 m2) (Campbell et al., 2013). However, this 
association was no longer statistically significant adjustment for the hemoglobin level 
(Campbell et al., 2013). In the current analysis, we did not find a perspective significantly 
association between the estimated GFR and depressive symptoms. Our finding was 
consistent with previous studies (Campbell et al., 2013; Martens et al., 2016).  
 Previous studies on the association of cystatin C with depressive symptoms are lacking. 
One study conducted by Minev et al. reported that a high level of cystatin C (>1.25 mg/l) 
increased the risk of depressive symptoms 2-fold during a 6-year follow-up in the 
American healthy elders (Minev et al., 2010). In addition, the Confucius Hometown 
Aging Project showed that a high serum cystatin C level and impaired kidney function 
were longitudinally associated with incident geriatric depressive symptoms among 
Chinese older adults (Wu et al., 2018). However, that study did not compare the relative 
association of cystatin C, BUN and the estimated GFR with the risk of new-onset 
depressive symptoms. Our results were robust to statistical adjustment of a series of 
confounders. Our results provide the new evidence that cystatin C increases the risk of 
depressive symptoms in a middle-aged population. Further research is needed to 
validate our findings regarding the association between renal function and depressive 
symptoms; this relationship has not been thoroughly explored among the elderly. 
 
Cystatin C as a measure of renal function overcomes the limitations of using the 
creatinine level because C concentration is not influenced by age, sex, or body mass 
(Fliser and Ritz, 2001). We also used restricted cubic splines to estimate the trend in the 
risk for depressive symptoms. The cystatin C concentration was confirmed to have a 
linear relationship with the risk of depressive symptoms. These findings were in 
alignment with prior studies that reported a linear relationship between cystatin C and 
an increased the risk of heart failure (Sarnak et al., 2005), hypertension (Kestenbaum et al., 
2008), cardiovascular disease and mortality (Shlipak et al., 2005).  
 
Several potential mechanisms may explain the association between cystatin C and 
depressive symptoms. First, cystatin C was used as an index of cerebral small vessel 
disease (Wada et al., 2010), which has been associated with incident depressive symptoms 
(van Sloten et al., 2015); this relationship is termed the “vascular depressive symptoms 
hypothesis (Alexopoulos, 2006).” In addition, physiological factors such as endothelial 
dysfunction and inflammation, have both linked to cystatin C (Balta et al., 2013; Zhang et 
al., 2016) and depressive symptoms (Al Shweiki et al., 2017; Bouzinova et al., 2014; Miller 
and Raison, 2016). 
 
4.2. Limitations 
There were several limitations. First, depressive symptoms measured by CES-D are not 
equivalent to a clinical diagnosis of major depressive symptoms. Second, depressive 
symptoms tend to fluctuate over time (White et al., 2016), and we did not assess the 
variability in depressive symptoms. Additionally, owing to the observational nature of 
our investigation, unmeasured potential confounding factors such as physical activity 
may still be present. Several important strengths of this study were the prospective 
design, and the large sample size and the use of the validated CES-D to assess 
depressive symptoms in 28 provinces in China. An additional strength is the complete 
assessment of renal function, which included cystatin C, BUN, and estimated GFR. To 
the best of our knowledge, this study is first to explore the association between cystatin 
C and depressive symptoms in a large cohort with normal renal function. 
 
4.3. Conclusions 
Our study demonstrated that cystatin C, a sensitive measure of renal function, is 
significantly associated with future depressive symptoms in the general population with 
relatively normal renal function. It is clinically important for individuals with normal 
renal function but high cystatin C to treat depressive symptoms and improve the quality 
of life. 
 
  
Acknowledgments 
The China Health and Retirement Longitudinal Study was developed by a team of 
researchers based at Peking University. The funding is provided by the National 
Institute on Aging (grant numbers: 1-R21-AG031372-01, 1-R21-AG033675-01-A1, 1-
R01-AG037031-01 and 1-R01-AG037031-03S1), the National Natural Science 
Foundation of China (grant numbers: 70773002, 70910107022 and 71130002), the 
World Bank (grant numbers: 7145915 and 7159234), and Peking University. We 
sincerely thank those who participated in data collection and management. 
 
Sources of Funding 
This work was supported by The Program of Natural Science Fund of China (grant 
numbers: 81530087). 
 
Declarations  
The authors declare that there is no duality of interest associated with this manuscript. 
 
  
References:   
Abdel-Kader, K., Unruh, M.L., Weisbord, S.D., 2009. Symptom burden, depression, and quality of life 
in chronic and end-stage kidney disease. Clin J Am Soc Nephro 4 (6), 1057-1064. 
Al Shweiki, M.H.D.R., Oeckl, P., Steinacker, P., Hengerer, B., Schonfeldt-Lecuona, C., Otto, M., 2017. 
Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from 
proteomics studies. Expert Rev Proteomic 14 (6), 499-514. 
Alexopoulos, G.S., 2006. The vascular depression hypothesis: 10 years later. Biol Psychiat 60 (12), 1304-
1305. 
Andresen, E.M., Malmgren, J.A., Carter, W.B., Patrick, D.L., 1994. Screening for depression in well 
older adults - evaluation of a short-form of the CES-D (Center for Epidemiologic Studies 
Depression Scale). Am J Prev Med 10 (2), 77-84. 
Balta, S., Demirkol, S., Ay, S.A., Cakar, M., Sarlak, H., Celik, T., 2013. Serum cystatin-c levels correlate 
with endothelial dysfunction in patients with the metabolic syndrome. J Intern Med 274 (2), 
200-201. 
Boey, K.W., 1999. Cross-validation of a short form of the CES-D in chinese elderly. Int J Geriatr 
Psychiatry 14 (8), 608-617. 
Bouzinova, E.V., Norregaard, R., Boedtkjer, D.M.B., Razgovorova, I.A., Moeller, A.M.J., Kudryavtseva, 
O., et al., 2014. Association between endothelial dysfunction and depression-like symptoms in 
chronic mild stress model of depression. Psychosom Med 76 (4), 268-276. 
Buchman, A.S., Tanne, D., Boyle, P.A., Shah, R.C., Leurgans, S.E., Bennett, D.A., 2009. Kidney function 
is associated with the rate of cognitive decline in the elderly. Neurology 73 (12), 920-927. 
Campbell, K.H., Huang, E.S., Dale, W., Parker, M.M., John, P.M., Young, B.A., et al., 2013. Association 
between estimated GFR, health-related quality of life, and depression among older adults with 
diabetes: the Diabetes and Aging Study. Am J Kidney Dis 62 (3), 541-548. 
Chen, H., Mui, A.C., 2014. Factorial validity of the center for epidemiologic studies depression scale 
short form in older population in China. Int Psychogeriatr 26 (1), 49-57. 
Cheng, S.T., Chan, A.C., 2005. The center for epidemiologic studies depression scale in older chinese: 
thresholds for long and short forms. Int J Geriatr Psychiatry 20 (5), 465-470. 
Fischer, M.J., Kimmel, P.L., Greene, T., Gassman, J.J., Wang, X.L., Brooks, D.H., et al., 2010. 
Sociodemographic factors contribute to the depressive affect among african americans with 
chronic kidney disease. Kidney Int 77 (11), 1010-1019. 
Fischer, M.J., Xie, D.W., Jordan, N., Kop, W.J., Krousel-Wood, M., Tamura, M.K., et al., 2012. Factors 
associated with depressive symptoms and use of antidepressant medications among participants 
in the chronic renal insufficiency cohort (CRIC) and hispanic-CRIC studies. Am J Kidney Dis 
60 (1), 27-38. 
Fliser, D., Ritz, E., 2001. Serum cystatin c concentration as a marker of renal dysfunction in the elderly. 
Am J Kidney Dis 37 (1), 79-83. 
Harel, O., Zhou, X.H., 2007. Multiple imputation: review of theory, implementation and software. Stat 
Med 26 (16), 3057-3077. 
Harrell, Frank E, 2010. Regression modeling strategies: with applications to linear models, logistic 
regression, and survival analysis. Springer. 
Hill, N.R., Fatoba, S.T., Oke, J.L., Hirst, J.A., O'Callaghan, C.A., Lasserson, D.S., et al., 2016. Global 
prevalence of chronic kidney disease - a systematic review and meta-analysis. Plos One 11 (7), 
e0158765. 
Ix, J.H., Shlipak, M.G., Chertow, G.M., Whooley, M.A., 2007. Association of cystatin c with mortality, 
cardiovascular events, and incident heart failure among persons with coronary heart disease - 
data from the Heart and Soul Study. Circulation 115 (2), 173-179. 
Kestenbaum, B., Rudser, K.D., de Boer, I.H., Peralta, C.A., Fried, L.F., Shlipak, M.G., et al., 2008. 
Differences in kidney function and incident hypertension: the Multi-Ethnic Study of 
Atherosclerosis. Annals of Internal Medicine 148 (7), 501-508. 
Lee, M.C., Wu, S.F.V., Hsieh, N.C., Tsai, J.M., 2016. Self-management programs on eGFR, depression, 
and quality of life among patients with chronic kidney disease: a meta-analysis. Asian Nurs Res 
10 (4), 255-262. 
Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Y.L., Castro, A.F., 3rd, Feldman, H.I., et al., 2009. A 
new equation to estimate glomerular filtration rate. Ann Intern Med 150 (9), 604-612. 
Liu, Q., Li, Y.X., Hu, Z.H., Jiang, X.Y., Li, S.J., Wang, X.F.J.N.L., 2018. Reduced estimated glomerular 
filtration rate is associated with depressive symptoms in elder chinese: a population-based cross-
sectional study. Neurosci Lett. 666, 127-132. 
Lopez-Giacoman, S., Madero, M., 2015. Biomarkers in chronic kidney disease, from kidney function to 
kidney damage. World J Nephrol 4 (1), 57-73. 
Macedo, E., 2011. Blood urea nitrogen beyond estimation of renal function. Crit Care Med 39 (2), 405-
406. 
Martens, R.J.H., Kooman, J.P., Stehouwer, C.D.A., Dagnelie, P.C., Kallen, C.J.H.V.D., Kroon, A.A., et 
al., 2016. Albuminuria is associated with a higher prevalence of depression in a population-
based cohort study: the Maastricht Study. Nephrol Dial Transplant 33(1), 128-138. 
Matsushita, K., Mahmoodi, B.K., Woodward, M., Emberson, J.R., Jafar, T.H., Jee, S.H., et al., 2012. 
Comparison of risk prediction using the CKD-EPI equation and the mdrd study equation for 
estimated glomerular filtration rate. JAMA 307 (18), 1941-1951. 
McNutt, L.A., Wu, C., Xue, X., Hafner, J.P., 2003. Estimating the relative risk in cohort studies and 
clinical trials of common outcomes. Am J Epidemiol 157 (10), 940-943. 
Miller, A.H., Raison, C.L., 2016. The role of inflammation in depression: from evolutionary imperative 
to modern treatment target. Nat Rev Immunol 16 (1), 22-34. 
Minev, E., Unruh, M., Shlipak, M.G., Simsonick, E., Yaffe, K., Leak, T.S., et al., 2010. Association of 
cystatin c and depression in healthy elders: the Health, Aging and Body Composition Study. 
Nephron Clinical Practice 116 (3), C241-C246. 
Odden, M.C., Whooley, M.A., Shlipak, M.G., 2006. Depression, stress, and quality of life in persons 
with chronic kidney disease: the Heart and Soul Study. Nephron Clin Pract 103 (1), c1-7. 
Palmer, S., Vecchio, M., Craig, J.C., Tonelli, M., Johnson, D.W., Nicolucci, A., et al., 2013. Prevalence 
of depression in chronic kidney disease: systematic review and meta-analysis of observational 
studies. Kidney Int 84 (1), 179-191. 
Rule, A.D., Bailey, K.R., Lieske, J.C., Peyser, P.A., Turner, S.T., 2013. Estimating the glomerular 
filtration rate from serum creatinine is better than from cystatin c for evaluating risk factors 
associated with chronic kidney disease. Kidney Int 83 (6), 1169-1176. 
Sarnak, M.J., Katz, R., Stehman-Breen, C.O., Fried, L.F., Jenny, N.S., Psaty, B.M., et al., 2005. Cystatin 
c concentration as a risk factor for heart failure in older adults. Ann Intern Med. 142 (7), 497-
505. 
Shardlow, A., McIntyre, N.J., Fraser, S.D.S., Roderick, P., Raftery, J., Fluck, R.J., et al., 2017. The clinical 
utility and cost impact of cystatin c measurement in the diagnosis and management of chronic 
kidney disease: a primary care cohort study. Plos Med 14 (10), e1002400. 
Shen, Y.Y., Yeatts, D.E., 2013. Social support and life satisfaction among older adults in china: family-
based support versus community-based support. Int J Aging Hum Dev 77 (3), 189-209. 
Shlipak, M.G., Sarnak, M.J., Katz, R., Fried, L.F., Seliger, S.L., Newman, A.B., et al., 2005. Cystatin c 
and the risk of death and cardiovascular events among elderly persons. New Engl J Med 352 
(20), 2049-2060. 
Stevens, L.A., Coresh, J., Greene, T., Levey, A.S., 2006. Medical progress - assessing kidney function - 
measured and estimated glomerular filtration rate. New Engl J Med 354 (23), 2473-2483. 
Tong, A., Sainsbury, P., Chadban, S., Walker, R.G., Harris, D.C., Carter, S.M., et al., 2009. Patients' 
experiences and perspectives of living with ckd. Am J Kidney Dis 53 (4), 689-700. 
Traynor, J., Mactier, R., Geddes, C.C., Fox, J.G., 2006. How to measure renal function in clinical practice. 
BMJ 333 (7571), 733-737. 
Tsai, Y.C., Chiu, Y.W., Hung, C.C., Hwang, S.J., Tsai, J.C., Wang, S.L., et al., 2012. Association of 
symptoms of depression with progression of ckd. Am J Kidney Dis 60 (1), 54-61. 
Tu, R.P., Inoue, Y., Yazawa, A., Hao, X.N., Cai, G.X., Li, Y.P., et al., 2018. Social participation and the 
onset of hypertension among the middle-aged and older population: evidence from the China 
Health and Retirement Longitudinal Study. Geriatr Gerontol Int 18 (7), 1093-1099. 
van Sloten, T.T., Sigurdsson, S., van Buchem, M.A., Phillips, C.L., Jonsson, P.V., Ding, J., et al., 2015. 
Cerebral small vessel disease and association with higher incidence of depressive symptoms in 
a general elderly population: the AGES-Reykjavik Study. Am J Psychiat 172 (6), 570-578. 
Voskoboev, N.V., Larson, T.S., Rule, A.D., Lieske, J.C., 2012. Analytic and clinical validation of a 
standardized cystatin c particle enhanced turbidimetric assay (PETIA) to estimate glomerular 
filtration rate. Clin Chem Lab Med 50 (9), 1591-1596. 
Wada, M., Nagasawa, H., Kawanami, T., Kurita, K., Daimon, M., Kubota, I., et al., 2010. Cystatin c as 
an index of cerebral small vessel disease: results of a cross-sectional study in community-based 
japanese elderly. Eur J Neurol 17 (3), 383-390. 
White, J., Zaninotto, P., Walters, K., Kivimaki, M., Demakakos, P., Biddulph, J., et al., 2016. Duration 
of depressive symptoms and mortality risk: the English Longitudinal Study of Ageing (ELSA). 
Br J Psychiat 208 (4), 337-342. 
Wu, C.K., Lin, J.W., Caffrey, J.L., Chang, M.H., Hwang, J.J., Lin, Y.S., 2010. Cystatin c and long-term 
mortality among subjects with normal creatinine-based estimated glomerular filtration rates. J 
Am Coll Cardiol 56 (23), 1930-1936. 
Wu, L., Yan, Z., Jiang, H., Xing, H., Li, H., Qiu, C.J.B.g., 2018. Serum cystatin c, impaired kidney 
function, and geriatric depressive symptoms among older people living in a rural area: a 
population-based study. BMC Geriatr 18 (1), 265. 
Yang, F., Qian, D., Hu, D., Hou, M., Chen, S., Wang, P., et al., 2016. Prevalence of cardiovascular disease 
risk factor clustering in Chinese adults. Clinical Trials and Regulatory Science in Cardiology 
15 (C), 1-6. 
Ye, S., Muntner, P., Shimbo, D., Judd, S.E., Richman, J., Davidson, K.W., et al., 2013. Behavioral 
mechanisms, elevated depressive symptoms, and the risk for myocardial infarction or death in 
individuals with coronary heart disease: the REGARDS (reason for geographic and racial 
differences in stroke) study. J Am Coll Cardiol 61 (6), 622-630. 
Zhang, M., Li, Y.L., Yang, X., Shan, H., Zhang, Q.H., Ming, Z.J., et al., 2016. Serum cystatin c as an 
inflammatory marker in exacerbated and convalescent copd patients. Inflammation 39 (2), 625-
631. 
Zhao, Y., Hu, Y., Smith, J.P., Strauss, J., Yang, G., 2014. Cohort profile: the China Health and Retirement 
Longitudinal Study (CHARLS). Int J Epidemiol 43 (1), 61-68. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure Legend  
 
Figure 1. Crude Incidence Rate of Depressive Symptoms According to Quintile of 
Measures of Renal Function. GFR denotes estimated glomerular filtration rate, and BUN means 
blood urea nitrogen. 
 
  
 
Figure 2. Multivariable Adjusted Incidence Risk Ratio of New-Onset Depressive 
Symptoms According to Cystatin C levels. Solid-red lines are multivariable-adjusted 
incidence risk ratio, and dashed lines indicate 95% confidence intervals derived from restricted 
cubic spline regression with five knots chosen by Akaike information criterion. Cystatin C of 1.00 
mg/liter was used as the reference because it approximated the median value. The graphs are 
truncated at the 1st and 99th percentiles. The modified Poisson regression with robust error 
variance adjusted for age, sex, education, marital status, living area, alcohol use, smoking status, 
retirement status, social participation, family-based social support, self-reported health, life 
satisfaction, history of hypertension, diabetes, dyslipidemia, coronary artery heart disease, stroke, 
and chronic obstructive pulmonary disorder, systolic blood pressure, body-mass index, total, low-
density, high-density lipoprotein cholesterol levels, log-transformed triglyceride level, log-
transformed C-reactive protein level and baseline CES-D score. 
 
 Figure 3. Association of Renal Function with New-Onset Depressive Symptoms on a 
Continuous Scale. The incidence risk ratio (IRR) have been adjusted for age, sex, education, 
marital status, living area, alcohol use, smoking status, retirement status, social participation, 
family-based social support, self-reported health, life satisfaction, history of hypertension, diabetes, 
dyslipidemia, coronary artery heart disease, stroke, and chronic obstructive pulmonary disorder, 
systolic blood pressure, body-mass index, total, low-density, high-density lipoprotein cholesterol 
levels, log-transformed triglyceride level, log-transformed C-reactive protein level and baseline 
CES-D score. 
 
 
 
  
Tables 
Table 1. Baseline Characteristics of Middle-aged Participants in the China Health and Retirement Longitudinal 
Study, According to Quintiles of Cystatin C 
Characteristic 
Quintile 1 
(≤0.82) 
Quintile 2 
(0.83-0.92) 
Quintile 3 
(0.93-1.01) 
Quintile 4 
(1.02-1.14) 
Quintile 5 
(≥1.15) 
P for   
trend 
No. of participants 1047 1022 1020 1018 1004  
Age —years 54.4 ± 7.6 56.2 ± 7.9 58.1 ± 8.1 60.9 ± 8.7 66.0 ± 9.2 <0.001 
   Median (min – max) 53 (45 – 82) 55 (45 – 82) 57 (45 – 83) 60 (45 – 88) 67 (45 – 93)  
Male sex —no. (%) 352 (33.6) 437 (42.8) 541 (53.0) 586 (57.6) 675 (67.2) <0.001 
Area urban —no. (%) 451 (43.1) 395 (38.6) 401 (39.3) 393 (38.6) 389 (38.7) 0.068 
Education —no. (%)      <0.001 
   No formal education  392 (37.4) 421 (41.2) 428 (42.0) 451 (44.3) 477 (47.5)  
   Primary school 211 (20.2) 203 (19.9) 237 (23.2) 233 (22.9) 264 (26.3)  
   Middle school or above 444 (42.4) 398 (38.9) 355 (34.8) 334 (32.8) 263 (26.2)  
Smoking status —no. (%)      <0.001 
   Never  762 (72.8) 683 (66.8) 582 (57.1) 519 (51.0) 475 (47.3)  
   Former  66 (6.3) 69 (6.8) 91 (8.9) 107 (10.5) 112 (11.2)  
   Current  219 (20.9) 270 (26.4) 347 (34.0) 392 (38.5) 417 (41.5)  
Alcohol use —no. (%)      <0.001 
   Never 742 (70.9) 686 (67.1) 631 (61.9) 627 (61.6) 638 (63.5)  
   <1 times/month 72 (6.9) 71 (6.9) 84 (8.2) 84 (8.3) 82 (8.2)  
   ≥1 times/month 233 (22.3) 265 (25.9) 305 (29.9) 307 (30.2) 284 (28.3)  
Married —no. (%) 978 (93.4) 936 (91.6) 933 (91.5) 910 (89.4) 840 (83.7) <0.001 
Retired—no. (%)* 221 (21.2) 211 (20.7) 226 (22.2) 291 (28.6) 371 (37.0) <0.001 
Social participation—no. (%) 573 (54.7) 507 (49.6) 496 (48.6) 471 (46.3) 501 (49.9) 0.008 
Family-based social support       
Network size —log 1.2 ± 0.5 1.2 ± 0.5 1.2 ± 0.5 1.1 ± 0.5 1.1 ± 0.6 <0.001 
   Receiving help—no. (%)* 328 (31.3) 367 (35.9) 363 (35.6) 416 (40.9) 488 (48.6) <0.001 
Providing help—no. (%)* 474 (45.3) 418 (40.9) 404 (39.6) 370 (36.3) 319 (31.8) <0.001 
Self-reported health—no. (%)*      0.002 
   Very good/good 323 (30.9) 297 (29.1) 283 (27.7) 276 (27.1) 230 (22.9)  
   Fair 556 (53.1) 536 (52.4) 536 (52.5) 554 (54.4) 550 (54.8)  
   Poor/very poor 168 (16.0) 189 (18.5) 201 (19.7) 188 (18.5) 223 (22.2)  
Life satisfaction—no. (%)*      0.493 
Completely/very satisfied 246 (25.0) 235 (24.9) 248 (26.6) 258 (27.6) 234 (26.1)  
Somewhat satisfied 649 (66.0) 616 (65.3) 596 (64.0) 592 (63.4) 575 (64.2)  
   Not very/not at all satisfied 88 (9.0) 93 (9.9) 87 (9.3) 84 (9.0) 87 (9.7)  
History of hypertension —no. (%) 214 (20.4) 212 (20.7) 234 (22.9) 249 (24.5) 287 (28.6) <0.001 
History of diabetes —no. (%) 72 (6.9) 49 (4.8) 57 (5.6) 39 (3.8) 50 (5.0) 0.029 
History of dyslipidemia —no. (%) 98 (9.4) 94 (9.2) 103 (10.1) 78 (7.7) 71 (7.1) 0.029 
History of CHD —no. (%) 51 (4.9) 74 (7.2) 90 (8.8) 100 (9.8) 115 (11.5) <0.001 
History of stroke —no. (%) 13 (1.2) 10 (1.0) 16 (1.6) 13 (1.3) 25 (2.5) 0.022 
History of COPD —no. (%) 90 (8.6) 82 (8.0) 107 (10.5) 121 (11.9) 136 (13.5) <0.001 
Body mass index —kg/m2* 24.4 ± 3.9 23.8 ± 3.6 23.6 ± 3.7 23.5 ± 4.1 22.9 ± 4.0 <0.001 
Systolic blood pressure —mm Hg* 127.4 ± 19.5 128.9 ± 20.5 130.0 ± 21.0 132.5 ± 22.1 134.1 ± 23.0 <0.001 
Diastolic blood pressure —mm Hg* 75.9 ± 11.4 75.9 ± 11.8 75.8 ± 12.0 76.5 ± 12.4 74.9 ± 12.5 0.289 
Total cholesterol — mg/dl 199.7 ± 40.7 192.2 ± 36.3 192.4 ± 37.8 191.2 ± 37.6 188.0 ± 39.0 <0.001 
LDL cholesterol — mg/dl* 116.3 ± 35.7 117.4 ± 33.0 116.8 ± 35.5 116.3 ± 34.7 114.2 ± 35.3 0.130 
HDL cholesterol —mg/dl* 48.4 ± 14.3 51.5 ± 14.6 51.1 ± 15.4 51.0 ± 15.1 51.6 ± 15.7 <0.001 
Triglycerides —log 4.9 ± 0.6 4.7 ± 0.5 4.7 ± 0.6 4.7 ± 0.5 4.6 ± 0.5 <0.001 
Fasting blood glucose —mg/dl* 116.3 ± 49.0 109.0 ± 32.8 108.3 ± 29.9 107.6 ± 26.7 106.3 ± 25.4 <0.001 
C-reactive protein —log 0.0 ± 1.0 0.0 ± 1.0 0.1 ± 0.9 0.2 ± 1.1 0.4 ± 1.1 <0.001 
Cystatin C —mg/liter 0.7 ± 0.1 0.9 ± 0.0 1.0 ± 0.0 1.1 ± 0.0 1.3 ± 0.2 <0.001 
Creatinine —mg/dl 0.7 ± 0.1 0.7 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.9 ± 0.2 <0.001 
BUN —mg/dl 14.5 ± 4.0 14.9 ± 3.8 15.6 ± 4.0 16.3 ± 4.5 17.1 ± 4.8 <0.001 
Estimated GFR —ml/min/1.73 m2 100.7 ± 11.5 97.5 ± 10.6 94.8 ± 10.9 90.0 ± 11.3 82.6 ± 12.5 <0.001 
Baseline CES-D score 5.1 ± 3.2 5.4 ± 3.4 5.2 ± 3.4 5.3 ± 3.3 5.3 ± 3.3 0.262 
Data are given as mean ± SD value or number (percentage) of participants.  
* Missing data: retired (n=1), receiving help (n=1), providing help (n=1), life satisfaction (n=407), body-mass 
index (n=581), systolic blood pressure (n=583), diastolic blood pressure (n=582), LDL cholesterol (n=1), HDL 
cholesterol (n=1), Fasting glucose (n=1). 
CHD denotes coronary artery heart disease, COPD denotes chronic obstructive pulmonary disease, LDL denotes 
low-density lipoprotein, HDL denotes high-density lipoprotein, BUN denotes blood urea nitrogen, GFR denotes 
glomerular filtration rate, and CES-D denotes Center for Epidemiologic Studies Depression Scale.  
C-reactive protein was measured in milligrams per liter. 
 
 Table 2. Risk of Depression According to Measures of Renal Function among Middle-aged Participants in the China 
Health and Retirement Longitudinal Study 
 Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Cystatin C - mg/liter 
Range of values  ≤0.82 0.83-0.92 0.93-1.01 1.02-1.14 ≥1.15 
No. at risk 1047 1022 1020 1018 1004 
No. of depression 344 363 347 345 347 
Incidence rate ratio (95% CI) 
Unadjusted 1.00 1.08 (0.96-1.22) 1.04 (0.92-1.17) 1.03 (0.91-1.17) 1.05 (0.93-1.19) 
Full adjusted† 1.00 1.08 (0.96-1.22) 1.09 (0.96-1.23) 1.11 (0.97-1.26) 1.18 (1.03-1.35) 
Blood Urea Nitrogen (BUB) - mg/dl 
Range of values  ≤12.0 12.1-14.12 14.13-16.16 16.17-19.1 ≥19.2 
No. at risk 1032 1015 1023 1031 1010 
No. of depression 399 363 318 334 332 
Incidence rate ratio (95% CI) 
Unadjusted 1.00 0.93 (0.83-1.04) 0.80 (0.71-0.91) 0.84 (0.75-0.94) 0.85 (0.76-0.96) 
Full adjusted† 1.00 0.96 (0.86-1.08) 0.86 (0.76-0.97) 0.91 (0.81-1.03) 0.92 (0.82-1.04) 
Estimated GFR - ml/min/1.73 m2 
Range of values  ≥104.43 98.36-104.42 91.58-98.35 82.72-91.57 ≤82.71 
No. at risk 1025 1020 1024 1020 1022 
No. of depression 348 351 359 346 342 
Incidence rate ratio (95% CI) 
Unadjusted 1.01 (0.90-1.15) 1.03 (0.91-1.16) 1.05 (0.93-1.18) 1.01 (0.90-1.14) 1.00 
Full adjusted† 1.10 (0.96-1.26) 1.15 (1.01-1.31) 1.13 (0.99-1.28) 1.03 (0.91-1.16) 1.00 
†Adjusted for age, sex, education, marital status, living area, alcohol use, smoking status, retirement status, social 
participation, family-based social support, self-reported health, life satisfaction, history of hypertension, diabetes, 
dyslipidemia, coronary artery heart disease, stroke, and chronic obstructive pulmonary disorder, systolic blood 
pressure, body-mass index, total, low-density, high-density lipoprotein cholesterol levels, log-transformed 
triglyceride level, log-transformed C-reactive protein level and baseline CES-D score. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Materials  
 
Figure  S1. Flow Diagram of the Participants Selection from the China Health and 
Retirement Longitudinal Study. 
 
 
 
 
Table S1. Incidence rate ratio (95% CI) of Depression According to Measures of Renal Function among Middle-aged Participants 
in the China Health and Retirement Longitudinal Study (n=4128) 
 Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 1-SD change 
Cystatin C - mg/liter  
Full adjusted† 1.00 1.10 (0.96-1.26) 1.04 (0.90-1.20) 1.13 (0.97-1.30) 1.20 (1.02-1.40) 1.06 (1.02-1.12) 
Blood Urea Nitrogen (BUB) - mg/dl  
Full adjusted† 1.00 0.96 (0.84-1.10) 0.91 (0.80-1.04) 0.94 (0.82-1.08) 0.95 (0.83-1.09) 0.99 (0.95-1.04) 
Estimated GFR - ml/min/1.73 m2  
Full adjusted† 1.17 (0.99-1.37) 1.19 (1.02-1.39) 1.19 (1.03-1.38) 1.02 (0.88-1.18) 1.00 1.06 (1.00-1.11) 
Data are incidence rate ratio and the 95% CI. 
†Adjusted for age, sex, education, marital status, living area, alcohol use, smoking status, retirement status, social participation, 
family-based social support, self-reported health, life satisfaction, history of hypertension, diabetes, dyslipidemia, coronary artery 
heart disease, stroke, and chronic obstructive pulmonary disorder, systolic blood pressure, body-mass index, total, low-density, 
high-density lipoprotein cholesterol levels, log-transformed triglyceride level, log-transformed C-reactive protein level and 
baseline CES-D score. 
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